Status:
COMPLETED
An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer
Lead Sponsor:
PharmaMar, Spain
Conditions:
Recurrent Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined patient groups, which are not representative for the whole patient population. Especially elderly patients ...
Detailed Description
Yondelis® (trabectedin) was approved (in combination with PLD) in the European community in December 2009 for the treatment of platinum-sensitive ovarian cancer relapse. Based on the outcomes of study...
Eligibility Criteria
Inclusion
- Women age \>18, no upper limit
- Patients with relapsed platinum-sensitive ovarian cancer
- Before inclusion in the NIS written informed consent must be given
Exclusion
- According to summary of product characteristics
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT01869400
Start Date
April 1 2013
End Date
February 1 2017
Last Update
April 6 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Praxis und Tagesklinik für gynäkologische Onkologie
Ebersberg, Bavaria, Germany, 85567
2
Diakoniekrankenhaus, Gynäkologie und Geburtshilfe
Rotenburg (Wümme), Lower Saxony, Germany, 27356